pertuzumab,pembrolizumab,dostarlimab,talazoparib,durvalumab,trastuzumab,olaparib,paclitaxel,neratinib,cemiplimab,ganetespib,irinotecan,tucatinib
gsk,bms,amgen,astrazeneca,daiichi sankyo,merck,roche
['i-spy', 'breast']
 great presentation by , highlighting promising signatures of response to neoadjuvant treatment among patients with high-risk hr+/her- breast cancer identified in i-spy2.
#asco22 
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.